Mirum Pharmaceuticals Stock Price, News & Analysis

Mirum Pharmaceuticals announced its participation in the NASPGHAN annual meeting (November 6-9, 2024) in Hollywood, Florida, where it will present LIVMARLI® (maralixibat) data for Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) treatments. The presentations will showcase clinical benefits and real-world evidence, including improvements in growth for PFIC patients, 7-year durability of benefits in ALGS patients, liver health improvements, enhanced quality of life, and impact on concomitant medication use for cholestatic pruritus treatment.

Mirum Pharmaceuticals (NASDAQ: MIRM) has announced inducement awards granted to four new employees on October 10, 2024. The awards, approved by the Compensation Committee of Mirum's Board of Directors, include:

1. Non-qualified stock options to purchase 34,100 shares of common stock
2. 17,050 restricted stock units (RSUs)

The stock options have an exercise price of $38.48 per share, matching Mirum's closing trading price on October 10, 2024. They will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over three years, with 33% vesting annually. Both are subject to continued employment with Mirum and the terms of the 2020 Inducement Plan and applicable award agreements.

Mirum Pharmaceuticals (Nasdaq: MIRM) announced that the FDA has granted Breakthrough Therapy Designation to volixibat for treating cholestatic pruritus in patients with primary biliary cholangitis (PBC). This designation is based on positive interim results from the Phase 2b VANTAGE study, which showed statistically significant improvement in pruritus compared to placebo. The study's confirmatory portion is ongoing, with enrollment expected to complete in 2026.

The Breakthrough Therapy Designation aims to expedite the development and review of drugs for serious diseases, requiring preliminary clinical evidence of substantial improvement over existing therapies. Mirum's chief medical officer, Dr. Joanne Quan, emphasized the importance of addressing PBC-related itch and the company's commitment to making volixibat available to patients as quickly as possible.

Mirum Pharmaceuticals (NASDAQ: MIRM) has granted inducement awards to seven new employees on September 10, 2024. The awards, approved by the Compensation Committee of Mirum's Board of Directors, consist of:

• Non-qualified stock options to purchase 19,700 shares of common stock
• 9,850 restricted stock units (RSUs)

The stock options have an exercise price of $41.77 per share, equal to Mirum's closing trading price on the grant date. They will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over three years, with 33% vesting annually. Both are subject to continued employment and the terms of Mirum's 2020 Inducement Plan.

Mirum Pharmaceuticals (Nasdaq: MIRM), a biopharmaceutical company specializing in rare and orphan diseases, has announced its participation in several upcoming investor conferences in September 2024. These include:

• Morgan Stanley 22nd Annual Global Healthcare Conference (Sept 4, 8:30 a.m. ET)
• H.C. Wainwright 26th Annual Global Investment Conference (Sept 10)
• Baird 2024 Global Healthcare Conference (Sept 11)
• 2024 Cantor Global Healthcare Conference (Sept 18, 1:55 p.m. ET)

Investors can find webcast links and additional information in the Investors and Media section of Mirum's corporate website.

Mirum Pharmaceuticals (Nasdaq: MIRM) has announced inducement grants for eight new employees under its 2020 Inducement Plan. The Compensation Committee approved these awards on August 9, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4). The grants include:

- Non-qualified stock options to purchase 59,000 shares of common stock
- 29,500 restricted stock units (RSUs)

The stock options have an exercise price of $40.02 per share, matching Mirum's closing price on August 9, 2024. They will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over three years, with 33% vesting annually. Both are subject to continued employment with Mirum.

Mirum Pharmaceuticals (Nasdaq: MIRM) reported strong Q2 2024 financial results, with global net product sales of $77.8 million, a 139% increase year-over-year. The company is on track to achieve its full-year guidance of $310-$320 million. Key highlights include:

1. LIVMARLI Q2 net sales of $47.2 million, up 45% from Q2 2023
2. CHOLBAM and CHENODAL Q2 net sales of $30.5 million
3. Positive interim results for volixibat in VISTAS PSC and VANTAGE PBC studies
4. LIVMARLI approved in Europe for PFIC in patients 3 months and older
5. LIVMARLI approved in the US for cholestatic pruritus in PFIC patients 12 months and older
6. Initiating Phase 3 EXPAND study for LIVMARLI in additional cholestatic pruritus settings
7. NDA submitted for chenodiol in CTX

Mirum's cash position remains strong at $295.4 million as of June 30, 2024.

Mirum Pharmaceuticals (NASDAQ: MIRM) has announced that it will release its second quarter 2024 financial results on August 7, 2024. The company will also host a conference call on the same day at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and recent corporate progress. Investors can access the call via a toll-free U.S. number or an international number, using the passcode 771307. Additionally, a webcast of the call will be available on Mirum's website in the Events & Presentations section, with a replay accessible for 30 days after the event.

Mirum Pharmaceuticals (Nasdaq: MIRM) announced FDA approval for an expanded label of LIVMARLI® (maralixibat) oral solution. The new label includes treatment for cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC) aged 12 months and older. This expansion, based on the MARCH Phase 3 study, also includes a higher concentration formulation of LIVMARLI.

Chris Peetz, CEO of Mirum, expressed enthusiasm about the launch of LIVMARLI for PFIC patients, emphasizing the importance of early treatment initiation to reduce suffering from pruritus associated with this rare liver disease. The expanded label allows for treatment in younger patients, aligning with the typical early diagnosis of PFIC.